Biodexa Pharmaceticals (BDRX) — Cash Flow-to-Debt Ratio
Biodexa Pharmaceticals (BDRX) has a Cash Flow-to-Debt Ratio of -0.34x as of December 2025, meaning its operating cash flow of $-2.33 Million could theoretically repay 0% of its total liabilities ($6.76 Million) in one year. See BDRX current assets to equity ratio to evaluate short-term liquidity relative to the company's equity base.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Biodexa Pharmaceticals Cash Flow-to-Debt Ratio (2012–2025)
Historical debt coverage capacity for Biodexa Pharmaceticals across 14 annual periods. Also explore BDRX net asset momentum to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Biodexa Pharmaceticals (2012–2025)
Year-by-year debt coverage analysis for Biodexa Pharmaceticals. For market capitalisation and broader financial context, see BDRX company net worth.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.80x | $-5.39 Million | $6.76 Million | ▲ +58.0% |
| 2024 | -1.90x | $-12.26 Million | $6.46 Million | ▼ -63.1% |
| 2023 | -1.16x | $-6.83 Million | $5.86 Million | ▲ +61.0% |
| 2022 | -2.98x | $-7.05 Million | $2.36 Million | ▼ -22.2% |
| 2021 | -2.44x | $-6.01 Million | $2.46 Million | ▲ +18.6% |
| 2020 | -3.00x | $-9.30 Million | $3.10 Million | ▼ -424.4% |
| 2019 | -0.57x | $-6.49 Million | $11.34 Million | ▲ +85.0% |
| 2018 | -3.82x | $-13.45 Million | $3.52 Million | ▼ -329.2% |
| 2017 | -0.89x | $-12.95 Million | $14.55 Million | ▲ +25.4% |
| 2016 | -1.19x | $-13.09 Million | $10.96 Million | ▼ -64.8% |
| 2015 | -0.72x | $-12.42 Million | $17.15 Million | ▲ +38.0% |
| 2014 | -1.17x | $-5.46 Million | $4.67 Million | ▼ -16.1% |
| 2013 | -1.00x | $-4.44 Million | $4.41 Million | ▼ -271.4% |
| 2012 | -0.27x | $-3.22 Million | $11.89 Million | — |